恩扎卢胺
Tier A — Act nowEnzalutamide · all drugs expiring in 2027 →
Targets：AR
Brand：安可坦、Xtandi、Enolen
Indications (approved)：激素敏感性前列腺肿瘤、去势抵抗性前列腺肿瘤、前列腺癌
Regional status
Synthetic routes & intermediates4 routes
Routes are ordered originator first, then optimised / process (non-patent) routes; each lists steps, overall yield and the intermediate table (code / CAS / name) — ready for supplier sourcing and RFQ. Rendered by this site from structured data; no third-party route graphics used.
| Code | CAS No. | Intermediate |
|---|---|---|
| ENZA-001 | 1427-07-2 | 2-fluoro-1-methyl-4-nitrobenzene |
| ENZA-002 | 403-24-7 | 2-fluoro-4-nitrobenzoic acid |
| ENZA-003 | 915087-24-0 | 2-fluoro-N-methyl-4-nitrobenzamide |
| ENZA-004 | 915087-25-1Available | 4-amino-2-fluoro-N-methylbenzamide |
| ENZA-005 | 75-86-5 | 2-hydroxy-2-methylpropanenitrile |
| ENZA-006 | 915087-32-0 | 4-((2-cyanopropan-2-yl)amino)-2-fluoro-N-methylbenzamide |
| ENZA-007 | 143782-23-4 | 4-isothiocyanato-2-(trifluoromethyl)benzonitrile |
| Code | CAS No. | Intermediate |
|---|---|---|
| ENZA-007 | 143782-23-4 | 4-isothiocyanato-2-(trifluoromethyl)benzonitrile |
| ENZA-008 | 112704-79-7 | 4-bromo-2-fluorobenzoic acid |
| ENZA-009 | 749927-69-3 | 4-bromo-2-fluoro-N-methylbenzamide |
| ENZA-010 | 62-57-7 | 2-amino-2-methylpropanoic acid |
| ENZA-011 | 1289942-66-0 | 2-((3-fluoro-4-(methylcarbamoyl)phenyl)amino)-2-methylpropanoic acid |
| ENZA-012 | 1332524-01-2 | methyl 2-((3-fluoro-4-(methylcarbamoyl)phenyl)amino)-2-methylpropanoate |
| Code | CAS No. | Intermediate |
|---|---|---|
| ENZA-011 | 1289942-66-0 | 2-((3-fluoro-4-(methylcarbamoyl)phenyl)amino)-2-methylpropanoic acid |
| ENZA-013 | 654-70-6 | 4-amino-2-(trifluoromethyl)benzonitrile |
| ENZA-014 | 1289942-55-7 | 4-((1-((4-cyano-3-(trifluoromethyl)phenyl)amino)-2-methyl-1-oxopropan-2-yl)amino)-2-fluoro-N-methylbenzamide |
| Code | CAS No. | Intermediate |
|---|---|---|
| ENZA-004 | 915087-25-1Available | 4-amino-2-fluoro-N-methylbenzamide |
| ENZA-007 | 143782-23-4 | 4-isothiocyanato-2-(trifluoromethyl)benzonitrile |
| ENZA-012 | 1332524-01-2 | methyl 2-((3-fluoro-4-(methylcarbamoyl)phenyl)amino)-2-methylpropanoate |
| ENZA-015 | 23426-63-3 | methyl 2-bromo-2-methylpropanoate |
Frequently asked questions
What are the approved indications of Enzalutamide?
Approved indications include: 激素敏感性前列腺肿瘤, 去势抵抗性前列腺肿瘤, 前列腺癌.
When does the Enzalutamide patent expire?
Based on public sources, the Enzalutamide patent expires in 2027.
How many synthesis routes are recorded for Enzalutamide?
4 synthesis routes are recorded; the shortest is 2 steps with 4 mg total yield. Intermediates in each route carry codes and CAS numbers.
Where can I buy Enzalutamide intermediates?
1 intermediate CAS of Enzalutamide are available through the Unibest supply network — see the route tables on this page and request a quote per CAS.
How do I get a quote for Enzalutamide intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-25